Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Filtrer les résultats de recherche
Sélectionner modèles de données

Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

10 Résultats de recherche.

CT Scans Week 38 Mepolizumab HES NCT00086658 - CT Scans Week 38

- 15/07/17 - 1 Formulaire, 1 Groupe Item, 5 Eléments de données, 1 Langue

Groupe Item: CT Scans

Study part: CT Scans Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

CT Scans Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - CT Scans Day 1 Pre-Infusion

- 11/06/17 - 1 Formulaire, 1 Groupe Item, 5 Eléments de données, 1 Langue

Groupe Item: CT Scans

Study part: CT Scans Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 38 Mepolizumab HES NCT00086658 - Neurological Examination Week 38

- 15/07/17 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 1 Langue

Groupe Item: Neurological Examination

Study part: Neurological Examination Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 16 Mepolizumab HES NCT00086658 - Neurological Examination Week 16

- 12/07/17 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 1 Langue

Groupe Item: Neurological Examination

Study part: Neurological Examination Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 8 Mepolizumab HES NCT00086658 - Neurological Examination Week 8

- 09/07/17 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 1 Langue

Groupe Item: Neurological Examination

Study part: Neurological Examination Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Week 4 Mepolizumab HES NCT00086658 - Neurological Examination Week 4

- 11/06/17 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 1 Langue

Groupe Item: Neurological Examination

Study part: Neurological Examination Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Neurological Examination Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Neurological Examination Day 1 Pre-Infusion

- 11/06/17 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 1 Langue

Groupe Item: Neurological Examination

Study part: Neurological Examination Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Follow- Up Form- Current Pregnancy Information Week 36 Mepolizumab HES NCT00086658 - Pregnancy Follow- Up Form- Current Pregnancy Information Week 36

- 15/07/17 - 1 Formulaire, 5 Groupes Item, 39 Eléments de données, 1 Langue

Groupes Item: FOLLOW-UP Pregnancy, INFANT INFORMATION, PREGNANCY INFORMATION, drug exposures pregnancy, information investigator

Study part: Pregnancy Follow- Up Form- Current Pregnancy Information Week 36/ Early Withdrawal Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Follow-Up Form- Current Pregnancy Information Week 38 Mepolizumab HES NCT00086658 - Pregnancy Follow-Up Form- Current Pregnancy Information Week 38

- 06/06/17 - 1 Formulaire, 5 Groupes Item, 39 Eléments de données, 1 Langue

Groupes Item: FOLLOW-UP Pregnancy, INFANT INFORMATION, PREGNANCY INFORMATION, drug exposures pregnancy, information investigator

Study part: Pregnancy Follow-Up Form- Current Pregnancy Information Week 38.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES Related Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - HES Related Medical Conditions Screening Visit

- 04/06/17 - 1 Formulaire, 8 Groupes Item, 34 Eléments de données, 1 Langue

Groupes Item: Cardiac disorders, NERVOUS SYSTEM DISORDERS, Skin diseases, GASTROINTESTINAL DISORDERS, MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, EYE DISORDERS, RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, medical history Hypereosinophilic Syndrome

Study part: HES Related Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.